Market Place
Sourcing Support
Halozyme Provides Update on Non-Binding Proposal with Evotec
18 Nov 2024 //
PR NEWSWIRE
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
15 Nov 2024 //
REUTERS
Halozyme Update On Licensee Co-Formulation Patent Hearing
24 Oct 2024 //
PR NEWSWIRE
Halozyme To Report Q3 2024 Financial And Operating Results
23 Oct 2024 //
PR NEWSWIRE
Argenx adds 4 new targets to Halozyme collab for $30M
04 Oct 2024 //
FIERCE PHARMA
FDA Approves Roche`s Subcutaneous OCREVUS ZUNOVO With ENHANZE
13 Sep 2024 //
PR NEWSWIRE
Halozyme to Present at Upcoming Investor Conferences
28 Aug 2024 //
PR NEWSWIRE
Argenx snares 2nd US nod for Vyvgart Hytrulo
22 Jun 2024 //
FIERCE PHARMA
Halozyme receives European patent for Enhanze drug delivery platform
07 Jun 2024 //
PHARMABIZ
Halozyme Raises 2024 Guidance, Updates 5-Year Financial Outlook
06 Jun 2024 //
PR NEWSWIRE
Halozyme: New European ENHANZE Patent Issued
05 Jun 2024 //
PR NEWSWIRE
Halozyme: Participating At Goldman Sachs Healthcare Conference
04 Jun 2024 //
PR NEWSWIRE
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
Halozyme To Participate In Upcoming Investor Conferences
08 May 2024 //
PR NEWSWIRE
Mahesh Krishnan Elected to Halozyme`s Board of Directors
25 Apr 2024 //
PR NEWSWIRE
Halozyme to Report First Quarter 2024 Financial and Operating Results
23 Apr 2024 //
PR NEWSWIRE
Halozyme to Participate in Upcoming Investor Conferences
27 Feb 2024 //
PR NEWSWIRE
Halozyme Reports Fourth Quarter And Full Year 2023 Financial Results
20 Feb 2024 //
PR NEWSWIRE
Halozyme To Report Fourth Quarter and Full Year 2023 Financial Results
08 Feb 2024 //
PR NEWSWIRE
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
30 Jan 2024 //
FIERCE PHARMA
Halozyme Announces Takeda Received European Commission Approval for HYQVIA
29 Jan 2024 //
PR NEWSWIRE
Halozyme Announces argenx Received Approval in Japan for VYVDURA
18 Jan 2024 //
PR NEWSWIRE
Roche’s Tecentriq SC receives EC approval for cancer treatment
17 Jan 2024 //
PHARMACEUTICAL TECHNOLOGY
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
12 Jan 2024 //
PR NEWSWIRE
Halozyme Announces argenx Receives European Commission Approval of VYVGART
16 Nov 2023 //
PRESS RELEASE
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration
06 Nov 2023 //
PR NEWSWIRE
Halozyme Reports Third Quarter 2023 Financial And Operating Results
06 Nov 2023 //
PR NEWSWIRE
Halozyme To Report Third Quarter 2023 Financial and Operating Results
30 Oct 2023 //
PR NEWSWIRE
Halozyme Announces Data of Auto-Injector Demonstrating Rapid Drug Delivery
16 Oct 2023 //
PR NEWSWIRE
Halozyme to Present at Upcoming Investor Conferences
31 Aug 2023 //
PR NEWSWIRE
England to rollout world-first seven-minute cancer treatment jab
30 Aug 2023 //
REUTERS
Halozyme Announces Approval of Roche`s Tecentriq® SC with ENHANZE
29 Aug 2023 //
PR NEWSWIRE
Halozyme Reports Second Quarter 2023 Financial And Operating Results
08 Aug 2023 //
PR NEWSWIRE
Halozyme To Report Second Quarter 2023 Financial and Operating Results
25 Jul 2023 //
PR NEWSWIRE
Halozyme Soars 5.4%: Is Further Upside Left in the Stock?
18 Jul 2023 //
YAHOO FINANCE
Positive Topline Data Reported from argenx`s ADHERE Study of VYVGART® Hytrulo
17 Jul 2023 //
PRESS RELEASE
Roche scores with subcutaneous version of MS drug Ocrevus
14 Jul 2023 //
FIERCE PHARMA
Halozyme Announces argenx Receives FDA Approval for VYVGART®
20 Jun 2023 //
PR NEWSWIRE
Halozyme to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Jun 2023 //
PR NEWSWIRE
Here’s Why Halozyme Therapeutics (HALO) Declined in Q1
22 May 2023 //
FINANCE YAHOO
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
10 May 2023 //
FINANCE YAHOO
Halozyme to Present at Upcoming Investor Conferences
03 May 2023 //
BUSINESSWIRE
Halozyme To Report First Quarter 2023 Financial and Operating Results
25 Apr 2023 //
PR NEWSWIRE
Halozyme`s investors will be pleased with 91% return over the last five years
18 Apr 2023 //
SIMPLYWALL
Halozyme Provides Update On Licensee co-formulation Patents in Europe
15 Mar 2023 //
PRESS RELEASE
Halozyme Provides Update On Licensee Co-Formulation Patent Hearing In Europe
15 Mar 2023 //
PR NEWSWIRE
Halozyme Reports Q4 And Full Year 2022 Financial and Operating Results
21 Feb 2023 //
PR NEWSWIRE
Halozyme to Report Fourth Quarter and Full Year 2022 Financial Results
07 Feb 2023 //
PR NEWSWIRE
Halozyme Appoints Barbara Duncan to its Board of Directors
06 Feb 2023 //
PR NEWSWIRE
Halozyme Announces Redemption Of 1.25% Convertible Senior Notes Due 2024
11 Jan 2023 //
PR NEWSWIRE
Halozyme Provides 2023 Financial Guidance and Outlook
10 Jan 2023 //
PR NEWSWIRE
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
PRESS RELEASE
Halozyme to Participate in Upcoming Investor Conferences
09 Nov 2022 //
PRNEWSWIRE
Halozyme to Report Third Quarter 2022 Financial and Operating Results
25 Oct 2022 //
PRNEWSWIRE
Halozyme Therapeutics Announces Upsize and Pricing of Private Offering of $625M
15 Aug 2022 //
PRNEWSWIRE
Halozyme Reports Second Quarter 2022 Financial And Operating Results
09 Aug 2022 //
PRNEWSWIRE
Halozyme to Report Second Quarter 2022 Financial and Operating Results
26 Jul 2022 //
PRNEWSWIRE
Halozyme to Participate in Goldman Sachs Healthcare Conference
08 Jun 2022 //
PRNEWSWIRE
Halozyme Announces Commercial Launch of TLANDO for TRT
07 Jun 2022 //
PRNEWSWIRE
